Medtronic Manipulated Bone Device Studies, Report Says

Law360, New York (October 25, 2012, 2:12 PM EDT) -- Medical device maker Medtronic Inc. may have manipulated company-sponsored health studies of its Infuse bone-growth product by editing the published content and paying doctors and researchers $210 million over 15 years for favorable reviews, according to a U.S. Senate Finance Committee report released Thursday.

The report, which was the result of a 16-month investigation into Medtronic, revealed questionable ties between the medical technology giant and the physician consultants who tested and reviewed its products, said Senate Finance Committee Chairman Max Baucus, D-Mont., and Sen. Chuck Grassley,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.